Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Neuropharmacology. 2008 Sep 10;55(8):1321–1328. doi: 10.1016/j.neuropharm.2008.08.031

Figure 3. Striatal ±8-OH-DPAT reduces D1R-mediated dyskinesia while increasing contralateral rotations.

Figure 3

Five min after intrastriatal, bilateral microinfusions of vehicle (VEH) or the 5-HT1AR agonist ±8-OH-DPAT (D; 5, 10, 15 μg/side), rats (n=9–10/treatment group) received treatment with the D1R agonist SKF81297 (0.8 mg/kg, sc). Lines depict the treatment means for (A) ALO AIMs ± SEM and (B) contralateral rotations ± SEM for medial forebrain bundle 6-OHDA-lesioned rats every 10 min for 2 hr. Main effects were determined by Kruskal-Wallis tests for ALO AIMs and two-way ANOVAs for rotations. Post hoc comparisons denote significant differences between treatments at the time points indicated.

* p < 0.05 for D-15 vs VEH; + p < 0.05 for D-10 vs. VEH; ×p < 0.05 for D-5 vs. VEH